ELOXX PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
ELOXX PHARMACEUTICALS, INC. (ELOX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 12-month period ending 2025-12-31, per its S-1 filed 2026-09-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-09-11
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2016-09-30 was 0.00%.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2015-03-31 was 0.00%.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2014-12-31 was 0.00%.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2014-09-30 was 0.00%.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2021 was 0.00%.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2020 was 0.00%.
- ELOXX PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2019 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|---|---|---|
| 2025-12-31 | 0.00% S-1 · filed 2026-09-11 | |||
| 2023-12-31 | 0.00% S-1 · filed 2026-09-11 | |||
| 2022-12-31 | 0.00% 10-K · filed 2023-03-31 | |||
| 2021-12-31 | 0.00% 10-K · filed 2023-03-31 | |||
| 2020-12-31 | 0.00% 10-K · filed 2022-03-30 | |||
| 2019-12-31 | 0.00% 10-K · filed 2022-03-30 | |||
| 2018-12-31 | 0.00% 10-K · filed 2021-03-12 | |||
| 2017-12-31 | 0.00% 10-K · filed 2020-03-06 | |||
| 2017-06-30 | 0.00% 10-K · filed 2017-10-13 | |||
| 2016-12-31 | 0.00% 10-K · filed 2019-03-14 | |||
| 2016-09-30 | 0.00% 10-Q · filed 2016-11-14 | |||
| 2016-06-30 | 0.00% 10-K · filed 2017-10-13 | |||
| 2015-12-31 | 0.00% 10-K · filed 2018-03-16 | |||
| 2015-06-30 | 0.00% 10-K · filed 2017-10-13 | |||
| 2015-03-31 | 0.00% 10-Q · filed 2015-05-14 | 0.00% 10-Q · filed 2015-05-14 | ||
| 2014-12-31 | 0.00% 10-Q · filed 2015-02-17 | 0.00% 10-Q · filed 2015-02-17 | ||
| 2014-09-30 | 0.00% 10-Q · filed 2014-11-14 | |||
| 2014-06-30 | 0.00% 10-K · filed 2016-10-13 | |||
| 2014-03-31 | 0.00% 10-Q · filed 2015-05-14 | 0.00% 10-Q · filed 2015-05-14 | ||
| 2013-12-31 | 0.00% 10-Q · filed 2015-02-17 | 0.00% 10-Q · filed 2015-02-17 | ||
| 2013-09-30 | 0.00% 10-Q · filed 2014-11-14 | |||
| 2013-06-30 | 0.00% 10-K · filed 2015-10-09 | |||
| 2012-09-30 | 0.00% 10-Q · filed 2013-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Tevogen Inc. (TVGN) | United States | $0.049B |